Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Published Online: 2018-11-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Andrew Hill•Charles Lance Cowey•Christopher D Lao•David Hogg•Dirk Schadendorf•Frank Stephen Hodi•Ivan Marquez-Rodas•James Larkin•Jasmine Rizzo•Jean-Jacques Grob•Jedd D Wolchok•Joel Jiang•John Wagstaff•Michael Smylie•Pier Francesco Ferrucci•Piotr Rutkowski•Reinhard Dummer•Rene Gonzalez•Vanna Chiarion-Sileni
